Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in China, has entered into a strategic partnership with Zhongheng Group (SHA: 600252) and Nanning Industrial Investment Unified Investment Management Co., Ltd, both of which are controlled by state-owned investment companies. The financial specifics of the agreement have not been disclosed.
As per the terms of the agreement, the trio will collaborate to establish a platform company focused on the overseas trade of mature drug products within the ASEAN region. The new entity will develop tailored product strategies for different countries, encompassing the selection of drugs, partnership models with local pharmaceutical enterprises, and the enhancement of local operations in ASEAN countries. The product portfolio will feature a range of mature drugs, including biosimilars, vaccines, first generic drugs, high-quality APIs, chemical drugs, traditional Chinese medicine, traditional Chinese patent medicines, and simple preparations and formula granules.- Flcube.com
